# BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients

> **NCT07071844** · PHASE2 · NOT_YET_RECRUITING · sponsor: **GERCOR - Multidisciplinary Oncology Cooperative Group** · enrollment: 162 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Trifluridine/tipiracil
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07071844
- **Lead sponsor:** GERCOR - Multidisciplinary Oncology Cooperative Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2025-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07071844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07071844, "BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07071844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*